Develops drugs for rare inflammatory diseases.
Dec 2025Revenue €29.3K/yrExpenses €45.7M/yr
No trend
Figures by year
When will InflaRx be profitable?
Its figures don’t show a steady enough trend to project a date. In the 12 months to Dec 2025, revenue was €29.3K and expenses €45.7M.
| Fiscal year to | Revenue | Expenses | Pre-tax profit |
|---|---|---|---|
| Dec 2025 | €29.3K | €45.7M | −€45.6M |
| Dec 2024 | €166K | €46.2M | −€46.1M |
| Dec 2023 | €63.1K | €42.7M | −€42.7M |
When the cash runs out, on the chart. A red line at the date the company’s cash would run out at its latest burn, so you can see whether it gets to break-even first. Part of a subscription.